ArticleAnnals of surgical oncology2026
Clinical Significance of an R1 Resection for Pancreatic Ductal Adenocarcinomas Treated by Intensive FOLFIRINOX Induction-Based Chemotherapy and Extended Pancreatectomies.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of R0/R1 Margin Status on Overall Survival in Node-Positive Resected Pancreatic Ductal Adenocarcinoma: Meta-Analysis.Annals of surgical oncology · 2026Pooled it
- ASO Author Reflections: R0 Resection Should Not Be Dismissed in Node-Positive Pancreatic Ductal Adenocarcinoma.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study assessed the prognostic significance of an R1 resection after intensive FOLFIRINOX (FX) neoadjuvant chemotherapy in patients with borderline (BL) and locally advanced pancreatic ductal adenocarcinomas.
methodsWe retrospectively analyzed data collected from January 2010 through December 2024 at a single center.
resultsA total of 219 consecutive patients (31 borderline and 188 locally advanced) underwent resection for pancreatic ductal adenocarcinoma after induction FX chemotherapy; the median number of preoperative cycles was 11 (range: 2-26). Venous resection was present in 191 patients (87.7%) and arterial resection in 141 patients (64.4%). R1 resection was observed in 73 patients (33.4%). The median overall survival (OS) from surgery was 30 months (95% confidence interval [CI] 21.3-38.6), with 1-, 3-, and 5-year survival rates of 77%, 45%, and 32%, respectively. R1 resection (hazard ratio [HR] 1.47; 95% CI 1.01-2.14; p = 0.004) was identified as an independent prognostic factor for OS, along with normalization of carbohydrate antigen 19-9 before surgery (HR 0.68; 95% CI 0.47-0.99; p = 0.04) and positive lymph nodes (HR 1.95; 95% CI 1.23-3.09; p = 0.004). R1 resection was associated with shorter OS (20 vs. 40 months; p < 0.0001) and disease-free survival (5 vs. 9 months, p = 0.005) than R0 resection. Patients with an R1 resection exhibited a lower histological and biological response to preoperative chemotherapy (p < 0.05).
conclusionsAn R1 resection after intensive induction chemotherapy by FX, undertaken in about one-third of resection cases, is a major prognostic factor associated with reduced long-term survival.
Indexed as
Identifiers
41329313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.